GENENTECH, INC.
- Country
- ๐บ๐ธUnited States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
- First Posted Date
- 2014-03-19
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 673
- Registration Number
- NCT02091141
- Locations
- ๐บ๐ธ
University Of Chicago Medical Center; Section Of Hematology/Oncology, Chicago, Illinois, United States
๐บ๐ธMD Anderson, Houston, Texas, United States
๐บ๐ธUniversity of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
- Conditions
- Interventions
- First Posted Date
- 2014-02-26
- Last Posted Date
- 2018-07-03
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 313
- Registration Number
- NCT02072226
- Locations
- ๐บ๐ธ
Riverside Methodist Hospital, Columbus, Ohio, United States
๐บ๐ธUniversity of Arizona, Tucson, Arizona, United States
๐บ๐ธHartford Hospital, Hartford, Connecticut, United States
A Study Evaluating the Effect of Formulation on the Bioavailability of Ipatasertib in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-02-14
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT02063581
Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors
- First Posted Date
- 2014-01-29
- Last Posted Date
- 2017-02-06
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT02048709
- Locations
- ๐บ๐ธ
Georgia Regents University, Augusta, Georgia, United States
A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort
- First Posted Date
- 2013-12-02
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 252
- Registration Number
- NCT01998841
- Locations
- ๐จ๐ด
Grupo Neurociencias de Antioquia, Medellin, Colombia
๐จ๐ดHospital San Juan de Dios, Yarumal, Colombia
๐จ๐ดClรญnica de Marly, Bogota, Colombia
A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-11-26
- Last Posted Date
- 2017-10-04
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT01995188
- Locations
- ๐บ๐ธ
Massachusetts General Hospital., Boston, Massachusetts, United States
๐บ๐ธThe Sarah Cannon Research Inst, Nashville, Tennessee, United States
๐บ๐ธDana Farber Cancer Inst., Boston, Massachusetts, United States
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2017-08-21
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 95
- Registration Number
- NCT01991210
- Locations
- ๐จ๐ฆ
Princess Margaret Hospital, Toronto, Ontario, Canada
๐บ๐ธUniversity of California Irvine Medical Center, Orange, California, United States
๐ต๐ฑWojskowy Instytut Medyczny Centralny Szpital Kliniczny MON, Warszawa, Poland
A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.
- Conditions
- Interventions
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01991184
- Locations
- ๐บ๐ธ
Oregon Health Sciences Uni, Portland, Oregon, United States
๐ฆ๐บLinear Clinical Research Limited, Nedlands, Western Australia, Australia
๐บ๐ธSarah Cannon Cancer Center - Tennessee Oncology, Pllc, Nashville, Tennessee, United States
A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2023-03-14
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 85
- Registration Number
- NCT01992653
- Locations
- ๐ซ๐ท
Hopital Henri Mondor, Unite Hemopathies lymphoides, Creteil, France
๐บ๐ธBanner MD Anderson Cancer Center, Greeley, Colorado, United States
๐บ๐ธThe University of Alabama at Birmingham, Birmingham, Alabama, United States
A Study of Quilizumab Versus Placebo in Patients With Refractory Chronic Spontaneous Urticaria
- First Posted Date
- 2013-11-20
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT01987947